ReviewGland surgery2026
Breast implant-associated late hematoma: a narrative review of case reports and case series.
Review in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Late hematoma after breast implantation presents with delayed breast swelling or periprosthetic fluid that is clinically indistinguishable from breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL), late seroma, infection, or tumor recurrence. This narrative review synthesized published case reports and small case series to describe clinical presentations, hypothesized mechanisms, diagnostic approaches, and management strategies. Methods: PubMed, Web of Science, and Cochrane Library were searched from inception to December 31, 2025. English-language case reports and case series documenting hematoma occurring ≥4 months after implantation were included. Two reviewers independently screened records and extracted data. Given the heterogeneity of uncontrolled case-level evidence, a qualitative descriptive synthesis was performed. Key Content and Findings: There were 37 articles involving 47 cases from 12 countries included. The median time from implantation to hematoma onset was 72.0 months. Patients typically presented with acute painful unilateral swelling. Features distinguishing late hematoma from BIA-ALCL included acute pain, absence of persistent effusion beyond 1 year, and magnetic resonance imaging (MRI) signal characteristics consistent with evolving blood products. Proposed mechanisms included capsular microfractures, chronic inflammation with neovascularization, external trauma, and iatrogenic factors such as anticoagulation. Ultrasound was the preferred initial screening tool; MRI provided definitive assessment of hematoma staging and implant integrity. Image-guided aspiration was essential to obtain fluid for cytology, microbiology, and CD30 immunohistochemistry to exclude BIA-ALCL. Surgical evacuation with capsulectomy was the most frequently reported definitive treatment; ultrasound-guided aspiration or arterial embolization were described in select patients with intact implants or poor surgical tolerance. Follow-up and recurrence data were inconsistently reported. Conclusions: Late hematoma should be considered in implant recipients with delayed swelling or periprosthetic fluid. Clinical evaluation, ultrasound, MRI, and image-guided aspiration guide management. Surgical evacuation with capsulectomy remains the primary reported treatment. These findings are descriptive only.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.